{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:59:49Z","timestamp":1790873989459,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,3]]},"abstract":"<jats:p>\n                    This study aimed to evaluate the safety of naphlimostat mesylate (NM) as an anticoagulant in vitro for emergency intensive care unit patients with coagulation dysfunction undergoing continuous renal replacement therapy (CRRT). Patients requiring CRRT and presenting with coagulation dysfunction, admitted to Dazhou Central Hospital\u2019s emergency intensive care unit in Sichuan Province between September 2021 and January 2023, were included. Patients were randomly assigned to either the NM group (experimental) or the sodium citrate group (control). Data on patient demographics, changes in coagulation factors, hemoglobin, platelets, inflammatory markers, and electrolytes during treatment were collected for both groups. A total of 89 patients participated, with 49 in the NM group and 40 in the sodium citrate group. Complete data were available for 39 patients in the NM group and 36 in the sodium citrate group. Data on filter usage, alterations in coagulation factors, hemoglobin, platelets, inflammatory markers, and electrolytes were collected throughout the treatment period. A total of 117 filters were used across both groups. The median filter duration was 25.5 (range 16.0\u201343.5) hours in the NM group and 28.5 (range 18.0\u201346.5) hours in the sodium citrate group. There was no statistically significant difference in daily filter usage between the groups (1.16\u2005\u00b1\u20050.76 vs 1.00\u2005\u00b1\u20050.55,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). NM demonstrated comparable anticoagulant efficacy to sodium citrate. Posttreatment, there were no significant differences between groups in prothrombin time (PT) (35.95\u2005\u00b1\u200533.14 vs 23.71\u2005\u00b1\u200519.37), activated partial thromboplastin time (55.65\u2005\u00b1\u200520.82 vs 55.65\u2005\u00b1\u200520.82), international normalized ratio (3.05\u2005\u00b1\u20052.83 vs 4.91\u2005\u00b1\u200510.60), hemoglobin (82.10\u2005\u00b1\u200515.01 vs 93.10\u2005\u00b1\u200526.86), platelet count (66.70\u2005\u00b1\u200559.87 vs 70.10\u2005\u00b1\u200548.85), serum sodium (138.80\u2005\u00b1\u20055.92 vs 142.00\u2005\u00b1\u20053.59), serum potassium (4.00\u2005\u00b1\u20050.52 vs 3.96\u2005\u00b1\u20050.61), serum calcium (1.13\u2005\u00b1\u20050.19 vs 0.99\u2005\u00b1\u20050.28), white blood cell count (10.82\u2005\u00b1\u20055.81 vs 12.54\u2005\u00b1\u20056.32), and neutrophil count (8.73\u2005\u00b1\u20055.05 vs 10.89\u2005\u00b1\u20055.94) levels (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u2005.05). NM is a safe and effective extracorporeal anticoagulant, demonstrating comparable anticoagulant efficacy to sodium citrate without increasing the risk of bleeding in patients with coagulation abnormalities undergoing CRRT.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000044932","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T20:05:14Z","timestamp":1759781114000},"page":"e44932","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of naphlimostat mesylate versus sodium citrate in CRRT for EICU patients with coagulation dysfunction: A STROBE-compliant observational study"],"prefix":"10.1097","volume":"104","author":[{"given":"Binglin","family":"Song","sequence":"first","affiliation":[{"name":"Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China"},{"name":"Dazhou Central Hospital, Dazhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan, China"},{"name":"Dazhou Central Hospital, Dazhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangrui","family":"Fu","sequence":"additional","affiliation":[{"name":"Dazhou Central Hospital, Dazhou, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-018-2112-z","article-title":"A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit.","volume":"22","author":"Peters","year":"2018","journal-title":"Crit Care"},{"key":"R2-20260526","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneph.2017.184","article-title":"Paradigms of acute kidney injury in the intensive care setting.","volume":"14","author":"Kellum","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"R3-20260526","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1525-139X.2010.00770.x","article-title":"Unfractionated heparin for hemodialysis: still the best option.","volume":"23","author":"Cronin","year":"2010","journal-title":"Semin Dial"},{"key":"R4-20260526","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2012.03.017","article-title":"Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.","volume":"60","author":"Shen","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R5-20260526","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/gfi004","article-title":"The heparins: all a nephrologist should know.","volume":"20","author":"Hetzel","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R6-20260526","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","article-title":"Heparin-induced thrombocytopenia.","volume":"2013","author":"Lee","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R7-20260526","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/sdi.12959","article-title":"Anticoagulation strategies in continuous renal replacement therapy.","volume":"34","author":"Legrand","year":"2021","journal-title":"Semin Dial"},{"key":"R8-20260526","first-page":"1","article-title":"KDIGO clinical practice guidelines for acute kidney injury.","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"R9-20260526","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10047-017-0968-3","article-title":"Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.","volume":"20","author":"Arimura","year":"2017","journal-title":"J Artif Organs"},{"key":"R10-20260526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5301\/ijao.5000191","article-title":"Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.","volume":"36","author":"Hwang","year":"2013","journal-title":"Int J Artif Organs"},{"key":"R11-20260526","doi-asserted-by":"crossref","first-page":"e108737","DOI":"10.1371\/journal.pone.0108737","article-title":"Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"R12-20260526","first-page":"25","article-title":"Chinese expert consensus on diagnosis and treatment of trauma-induced hypercoagulopathy.","volume":"8","author":"Song","year":"2021","journal-title":"Mil Med Res"},{"key":"R13-20260526","first-page":"108","article-title":"Intensivmedizin, notfallmedizin, schmerztherapie: AINS, Evidence-based renal replacement therapy \u2013 intermittent versus CRRT.","volume":"48","author":"J\u00f6rres","year":"2013","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"key":"R14-20260526","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","article-title":"Continuous renal replacement therapy: who, when, why, and how.","volume":"155","author":"Tandukar","year":"2019","journal-title":"Chest"},{"key":"R15-20260526","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/sdi.12963","article-title":"Continuous renal replacement therapy and extended indications.","author":"Ronco","year":"2021","journal-title":"Semin Dial"},{"key":"R16-20260526","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4037\/aacnacc2017386","article-title":"Considerations for medication management and anticoagulation during continuous renal replacement therapy.","volume":"28","author":"Thompson","year":"2017","journal-title":"AACN Adv Crit Care"},{"key":"R17-20260526","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40256-017-0229-0","article-title":"Thromboprophylaxis in extracorporeal circuits: current pharmacological strategies and future directions.","volume":"17","author":"Annich","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"R18-20260526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-016-1299-0","article-title":"Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials.","volume":"20","author":"Liu","year":"2016","journal-title":"Crit Care"},{"key":"R19-20260526","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1744-9987.2012.01101.x","article-title":"Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk.","volume":"17","author":"Kalb","year":"2013","journal-title":"Ther Apher Dial"},{"key":"R20-20260526","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00134-015-4099-0","article-title":"Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs.","volume":"41","author":"Bai","year":"2015","journal-title":"Intensive Care Med"},{"key":"R21-20260526","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2011.11.030","article-title":"Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.","volume":"59","author":"Wu","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R22-20260526","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jbcr\/irad196","article-title":"Filter lifespan, treatment effect, and influencing factors of continuous renal replacement therapy for severe burn patients.","volume":"45","author":"Yue","year":"2024","journal-title":"J Burn Care Res"},{"key":"R23-20260526","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40001-024-01660-7","article-title":"Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study.","volume":"29","author":"Liu","year":"2024","journal-title":"Eur J Med Res"},{"key":"R24-20260526","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5301\/IJAO.2011.8535","article-title":"Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.","volume":"34","author":"Maruyama","year":"2011","journal-title":"Int J Artif Organs"},{"key":"R25-20260526","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000420222","article-title":"Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.","volume":"93","author":"Ohtake","year":"1991","journal-title":"Contrib Nephrol"},{"key":"R26-20260526","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10157-018-1600-4","article-title":"The Japanese clinical practice guideline for acute kidney injury 2016.","volume":"22","author":"Doi","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"R27-20260526","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/ACO.0b013e3283620224","article-title":"Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details?","volume":"26","author":"Lanckohr","year":"2013","journal-title":"Curr Opin Anaesthesiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:49Z","timestamp":1786048189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":27,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044932","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"2024-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}